DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1192 Grumbach MM, Auchus RJ. Estrogen: Consequences and implications
of human mutations in synthesis and action. J Clin
Endocrinol Metab, 1999, 84:4677–4694.
Hall JM, McDonnell DP. The estrogen receptor β-isoform (ER
β) of the human estrogen receptor modulates ER β transcriptional
activity and is a key regulator of the cellular response
to estrogens and antiestrogens. Endocrinology, 1999, 140:
5566–5578.
Hall JM, McDonnel DP, Korach KS. Allosteric regulation of
estrogen receptor structure, function, and coactivator recruiment
by different estrogen response elements. Mol Endocrinol,
2002, 16:469–486.
Hammes SR. Steroids and oocyte maturation—a new look at an
old story. Molecular Endocrinology, 2004, 18:769–775.
Hammes SR, Levin ER. Extra-nuclear steroid receptors: Nature
and function. Endo Rev, 2007, 28:726–741.
Han W, Kang D, Lee KM, et al. Full sequencing analysis of
estrogen receptor-α gene polymorphism and its association
with breast cancer risk. Anticancer Res, 2003, 23:4703–4707.
Hanstein B, Djahansouzi S, Dall P, et al. Insights into the molecular
biology of the estrogen receptor define novel therapeutic
targets for breast cancer. Eur J Endocrinol, 2004, 150:243–255.
Harrington WR, Sheng S, Barnett DH, et al. Activities of estrogen
receptor α- and β-selective ligands at diverse estrogen
responsive gene sites mediating transactivation or transrepression.
Mol Cell Endocrinol, 2003, 206:13–22.
Haynes BP, Dowsett M, Miller WR, et al. The pharmacology of
letrozole. J Steroid Biochem Mol Biol, 2003, 87:35–45.
Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of
the vagina. Association of maternal stilbestrol therapy with
tumor appearance in young women. N Engl J Med, 1971,
284:878–881.
Herrington DM, Howard TD. ER-α variants and the cardiovascular
effects of hormone replacement therapy. Pharmacogenomics,
2003, 4:269–277.
Herrington DM, Klein, K.P. Pharmacogenetics of estrogen
replacement therapy. J Appl Physiol, 2001, 91:2776–2784.
Hewitt SC, Korach KS. Oestrogen receptor knockout mice:
Roles for oestrogen receptors α and β in reproductive tissues.
Reproduction, 2003, 125:143–149.
Hol T, Cox MB, Bryant HU, Draper MW. Selective estrogen
receptor modulators and postmenopausal women’s health.
J Womens Health, 1997, 6:523–531.
Hotchkiss J, Knobil E. The menstrual cycle and its neuroendocrine
control. In: The Physiology of Reproduction, 2nd ed.
(Knobil E, Neill JD, eds.), Raven Press, New York, 1994,
pp. 711–749.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen
plus progestin for secondary prevention of coronary heart
disease in post-menopausal women. Heart and Estrogen/
progestin Replacement Study (HERS) Research Group.
JAMA, 1998, 280:605–613.
Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of
tamoxifen for breast cancer: Twenty-eight years later. J Clin
Oncol, 1995, 13:513–529.
Jang GR, Benet LZ. Antiprogestin pharmacodynamics, pharmacokinetics,
and metabolism: Implications for their long-term
use. J Pharmacokinet Biopharm, 1997, 25:647–672.
Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens
as antitumor agents. Endocr Rev, 1990, 11:578–610.
SECTION V
HORMONES AND HORMONE ANTAGONISTS
Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen
receptor through phosphorylation by mitogen-activated protein
kinase. Science, 1995, 270:1491–1494.
Kettel LM, Roseff SJ, Berga SL, et al. Hypothalamic-pituitaryovarian
response to clomiphene citrate in women with polycystic
ovary syndrome. Fertil Steril, 1993, 59:532–538.
Knobil E. Patterns of hypophysiotropic signals and gonadotropin
secretion in the rhesus monkey. Biol Reprod, 1981, 24:44–49.
Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormonereplacement
therapy on fibrinolysis in postmenopausal
women. N Engl J Med, 1997, 336:683–690.
Kos M, Reid G, Denger S, Gannon F. Minireview: Genomic
organization of the human ERalpha gene promoter region. Mol
Endocrinol, 2001, 15:2057–2063.
Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in
mice by nongenotropic signaling of sex steroids. Science,
2002, 298:843–846.
Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the
ligand binding specificity and transcript tissue distribution of
estrogen receptors ER α and β. Endocrinology, 1997, 138:
863–870.
Kurabayashi T, Matsushita H, Tomita M, et al. Association of
vitamin D and estrogen receptor gene polymorphism with
the effects of long term hormone replacement therapy on
bone mineral density. J Bone Miner Metab, 2004, 22:
241–247.
Labrie F, El-Alfy M, Berger L, et al. The combination of a novel
selective estrogen receptor modulator with an estrogen protects
the mammary gland and uterus in a rodent model: The
future of post-menopausal women’s health? Endocrinology,
2003, 144:4700–4706.
Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in
post-menopausal breast cancer patients receiving tamoxifen.
Obstet Gynecol, 1993, 81:660–664.
Leonhardt SA, Edwards DP. Mechanism of action of progesterone
antagonists. Exp Biol Med, 2002, 227:969–980.
Levin E. G protein-coupled receptor 30: Estrogen receptor or
collaborator? Endocrinol, 2009, 150:1563–1565.
Levin ER. Rapid signaling by steroid receptors. Am J Physiol,
2008, 295:R1425–R1430.
Lewandowski S, Kalita K, Kaczmarek L. Estrogen receptor β.
Potential functional significance of a variety of mRNA isoforms.
FEBS Lett, 2002, 524:1–5.
Lobo RA, Stanczyk FZ. New knowledge in the physiology of
hormonal contraceptives. Am J Obstet Gynecol, 1994, 170:
1499–1507.
Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on
cardiovascular risk factors in postmenopausal women after 5 years
of treatment. J Natl Cancer Inst, 1994, 86:1534–1539.
Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone.
Recent Prog Horm Res, 2002, 57:385–409.
Manson JE, Martin KA. Clinical practice. Postmenopausal hormonereplacement
therapy. N Engl J Med, 2001, 345:34–40.
McDonnell DP, Goldman ME. RU486 exerts antiestrogenic
activities through a novel progesterone receptor A form-mediated
mechanism. J Biol Chem, 1994, 269:11945–11949.
McInerney EM, Weis KE, Sun J, et al. Transcription activation
by the human estrogen receptor subtype beta (ER beta) studied
with ER beta and ER alpha receptor chimeras. Endocrinology,
1998, 139:4513–4522.